Renibus Therapeutics

Renibus thanks patients who have participated or are enrolled in its clinical trials, saying their contributions help others through the knowledge gained.

Renibus Therapeutics announced participation at Oppenheimer Private Life.

Renibus Therapeutics said data on how RBT-1’s mechanism of action translated from animals to humans was selected for presentation at the ERA-EDTA Annual Congress.

Renibus Therapeutics announced an oral presentation of RBT-1 Phase 2 results at the 2023 Society of Critical Care Medicine (SCCM) meeting. The results met the primary biomarker endpoint and several key clinical endpoints.

Renibus Therapeutics reported that RBT-1 met its primary biomarker endpoint and several key clinical endpoints in a Phase 2 trial, supporting its potential to improve postoperative outcomes in cardiothoracic surgery.

Renibus Therapeutics reported interim RBT-1 results showing statistically significant reductions in ventilator and ICU days and a greater than 90% reduction in 30-day hospital readmissions.

Renibus says no jobs are currently available.

Renibus is a clinical-stage biopharmaceutical company developing products for renal and metabolic diseases. Its lead program is Veverimer, a non-absorbed polymer that binds hydrochloric acid (HCl).

Renibus has pipeline programs for cardio, renal, and metabolic diseases, including RBT-1, which completed the PROTECT Phase 3 trial in patients undergoing cardiac surgery.

Renibus Therapeutics lists its headquarters at 181 Grand Ave, Suite 225, Southlake, TX 76092. General inquiries: 682-285-1711; business development: busdev@renibus.com.

Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients’ lives to prevent disease progression, improve outcomes and protect against organ damage in cardiorenal diseases.